ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million

Reuters

Yesterday

ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million

ImmunityBio, Inc. (NASDAQ: IBRX) announced preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. The company reported preliminary net product revenue of approximately $38.3 million for the fourth quarter of 2025, representing a 20% increase over the $31.8 million recorded in the third quarter of 2025 and a 431% increase compared to the same period in 2024. For the full year, preliminary net product revenue reached $113 million, reflecting a 700% year-over-year increase. ImmunityBio also reported a 54% quarter-over-quarter unit volume growth rate during fiscal year 2025. As of December 31, 2025, the company had an estimated $242.8 million in cash, cash equivalents, and marketable securities. The company attributed this growth to increased adoption of ANKTIVA and highlighted recent regulatory approvals in Saudi Arabia, the U.S., the U.K., and conditional approval in the EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115898106) on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2603988488"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603988488\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603988488?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603988488","market":"us","top_or_hot":-1,"title":"ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> (NASDAQ: IBRX) announced preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. The company reported preliminary net product revenue of approximately $38.3 million for the fourth quarter of 2025, representing a 20% increase over the $31.8 million recorded in the third quarter of 2025 and a 431% increase compared to the same period in 2024. For the full year, preliminary net product revenue reached $113 million, reflecting a 700% year-over-year increase. ImmunityBio also reported a 54% quarter-over-quarter unit volume growth rate during fiscal year 2025. As of December 31, 2025, the company had an estimated $242.8 million in cash, cash equivalents, and marketable securities. The company attributed this growth to increased adoption of ANKTIVA and highlighted recent regulatory approvals in Saudi Arabia, the U.S., the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., and conditional approval in the EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115898106) on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> (NASDAQ: IBRX) announced preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. The company reported preliminary net product revenue of approximately $38.3 million for the fourth quarter of 2025, representing a 20% increase over the $31.8 million recorded in the third quarter of 2025 and a 431% increase compared to the same period in 2024. For the full year, preliminary net product revenue reached $113 million, reflecting a 700% year-over-year increase. ImmunityBio also reported a 54% quarter-over-quarter unit volume growth rate during fiscal year 2025. As of December 31, 2025, the company had an estimated $242.8 million in cash, cash equivalents, and marketable securities. The company attributed this growth to increased adoption of ANKTIVA and highlighted recent regulatory approvals in Saudi Arabia, the U.S., the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., and conditional approval in the EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115898106) on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL7z13Jc:1","article_id":"2603988488","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603988488","pubTimestamp":1768483866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunityBio, Inc.  announced preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. The company reported preliminary net product revenue of approximately $38.3 million for the fourth quarter of 2025, representing a 20% increase over the $31.8 million recorded in the third quarter of 2025 and a 431% increase compared to the same period in 2024. For the full year, preliminary net product revenue reached $113 million, reflecting a 700% year-over-year increase. ImmunityBio also reported a 54% quarter-over-quarter unit volume growth rate during fiscal year 2025. As of December 31, 2025, the company had an estimated $242.8 million in cash, cash equivalents, and marketable securities. The company attributed this growth to increased adoption of ANKTIVA and highlighted recent regulatory approvals in Saudi Arabia, the U.S., the U.K., and conditional approval in the EU.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"ImmunityBio报告2025年初步净产品收入为1.13亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million\n    \n\nImmunityBio, Inc. (NASDAQ: IBRX) announced preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. The company reported preliminary net product revenue of approximately $38.3 million for the fourth quarter of 2025, representing a 20% increase over the $31.8 million recorded in the third quarter of 2025 and a 431% increase compared to the same period in 2024. For the full year, preliminary net product revenue reached $113 million, reflecting a 700% year-over-year increase. ImmunityBio also reported a 54% quarter-over-quarter unit volume growth rate during fiscal year 2025. As of December 31, 2025, the company had an estimated $242.8 million in cash, cash equivalents, and marketable securities. The company attributed this growth to increased adoption of ANKTIVA and highlighted recent regulatory approvals in Saudi Arabia, the U.S., the U.K., and conditional approval in the EU.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115898106) on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}